Data from 11,765 patients treated at 280 cancer clinics over a decade have confirmed that omitting a bolus of 5-FU as part of a FOLFOX, FOLFIRI or FOLFIRINOX regimen in patients with metastatic gastrointestinal cancers does not shorten overall survival. The researchers also found that leaving out the bolus significantly reduced the incidence of neutropenia and thrombocytopenia, as well as use of granulocyte colony-stimulating factor.
The new evidence, published in the Journal of the National